Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 123

1.

A phase 2 study of ofatumumab (Arzerra®) in combination with a pan-AKT inhibitor (afuresertib) in previously treated patients with chronic lymphocytic leukemia (CLL).

Chen CI, Paul H, Le LW, Wei EN, Snitzler S, Wang T, Levina O, Kakar S, Lau A, Queau M, Johnston JB, Smith DA, Trudel S.

Leuk Lymphoma. 2018 Jun 19:1-9. doi: 10.1080/10428194.2018.1468892. [Epub ahead of print]

PMID:
29916761
2.

Predominant role of microglia in brain iron retention in Sanfilippo syndrome, a pediatric neurodegenerative disease.

Puy V, Darwiche W, Trudel S, Gomila C, Lony C, Puy L, Lefebvre T, Vitry S, Boullier A, Karim Z, Ausseil J.

Glia. 2018 Apr 6. doi: 10.1002/glia.23335. [Epub ahead of print]

PMID:
29624734
3.

Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation.

Chan H, Phillips M, Maganti M, Farooki S, Piza Rodriguez G, Masih-Khan E, Chen C, Prica A, Reece D, Tiedemann R, Trudel S, Kukreti V.

Clin Lymphoma Myeloma Leuk. 2018 Mar;18(3):225-234. doi: 10.1016/j.clml.2017.12.009. Epub 2018 Jan 5.

PMID:
29397346
4.

Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia.

Chen C, Siegel D, Gutierrez M, Jacoby M, Hofmeister CC, Gabrail N, Baz R, Mau-Sorensen M, Berdeja JG, Savona M, Savoie L, Trudel S, Areethamsirikul N, Unger TJ, Rashal T, Hanke T, Kauffman M, Shacham S, Reece D.

Blood. 2018 Feb 22;131(8):855-863. doi: 10.1182/blood-2017-08-797886. Epub 2017 Dec 4.

PMID:
29203585
5.

Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma.

van Beers EH, van Vliet MH, Kuiper R, de Best L, Anderson KC, Chari A, Jagannath S, Jakubowiak A, Kumar SK, Levy JB, Auclair D, Lonial S, Reece D, Richardson P, Siegel DS, Stewart AK, Trudel S, Vij R, Zimmerman TM, Fonseca R.

Clin Lymphoma Myeloma Leuk. 2017 Sep;17(9):555-562. doi: 10.1016/j.clml.2017.06.020. Epub 2017 Jul 4.

PMID:
28735890
6.

Temozolomide and Bevacizumab Induction before Chemoradiotherapy in Patients with Bulky Glioblastoma and/or with Severe Neurological Impairment.

Darmon I, Morisse MC, Coutte A, Blonski M, Le Rhun E, Taillandier L, Roufai DB, Desenclos C, Trudel S, Faivre JC, Blanchard N, Chauffert B, Boone M.

J Cancer. 2017 May 12;8(8):1417-1424. doi: 10.7150/jca.18339. eCollection 2017.

7.

Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates.

Kis O, Kaedbey R, Chow S, Danesh A, Dowar M, Li T, Li Z, Liu J, Mansour M, Masih-Khan E, Zhang T, Bratman SV, Oza AM, Kamel-Reid S, Trudel S, Pugh TJ.

Nat Commun. 2017 May 11;8:15086. doi: 10.1038/ncomms15086.

8.

The Importance of an In-depth Study of Immunoglobulin Gene Rearrangements When Ascertaining the Clonal Relationship between Concomitant Chronic Lymphocytic Leukemia and Multiple Myeloma.

Trudel S, Ghamlouch H, Dremaux J, Delette C, Harrivel V, Marolleau JP, Gubler B.

Front Immunol. 2016 Dec 27;7:625. doi: 10.3389/fimmu.2016.00625. eCollection 2016.

9.

Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients.

Kotchetkov R, Masih-Khan E, Chu CM, Atenafu EG, Chen C, Kukreti V, Trudel S, Tiedemann R, Reece DE.

Cancer Med. 2017 Jan;6(1):3-11. doi: 10.1002/cam4.799. Epub 2016 Nov 18.

10.

TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.

Petrova PS, Viller NN, Wong M, Pang X, Lin GH, Dodge K, Chai V, Chen H, Lee V, House V, Vigo NT, Jin D, Mutukura T, Charbonneau M, Truong T, Viau S, Johnson LD, Linderoth E, Sievers EL, Maleki Vareki S, Figueredo R, Pampillo M, Koropatnick J, Trudel S, Mbong N, Jin L, Wang JC, Uger RA.

Clin Cancer Res. 2017 Feb 15;23(4):1068-1079. doi: 10.1158/1078-0432.CCR-16-1700. Epub 2016 Nov 17.

11.

Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma.

Reece DE, Trieu Y, Masih-Khan E, Atenafu EG, Chen C, Prica A, Tiedemann R, Trudel S, Kukreti V.

Clin Lymphoma Myeloma Leuk. 2016 Jul;16(7):387-94. doi: 10.1016/j.clml.2016.04.012. Epub 2016 May 10.

PMID:
27349765
12.

Identification of human plasma cells with a lamprey monoclonal antibody.

Yu C, Liu Y, Chan JT, Tong J, Li Z, Shi M, Davani D, Parsons M, Khan S, Zhan W, Kyu S, Grunebaum E, Campisi P, Propst EJ, Jaye DL, Trudel S, Moran MF, Ostrowski M, Herrin BR, Lee FE, Sanz I, Cooper MD, Ehrhardt GR.

JCI Insight. 2016;1(3). pii: e84738. Epub 2016 Mar 17.

13.

One-step ligand exchange and switching from hydrophobic to water-stable hydrophilic superparamagnetic iron oxide nanoparticles by mechanochemical milling.

Korpany KV, Mottillo C, Bachelder J, Cross SN, Dong P, Trudel S, Friščić T, Blum AS.

Chem Commun (Camb). 2016 Feb 18;52(14):3054-7. doi: 10.1039/c5cc07107k.

PMID:
26794225
14.

Water oxidation catalysis: an amorphous quaternary Ba-Sr-Co-Fe oxide as a promising electrocatalyst for the oxygen-evolution reaction.

Zhang C, Berlinguette CP, Trudel S.

Chem Commun (Camb). 2016 Jan 25;52(7):1513-6. doi: 10.1039/c5cc09361a. Epub 2015 Dec 10.

PMID:
26659269
15.

FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing.

Wang Z, Dove P, Wang X, Shamas-Din A, Li Z, Nachman A, Oh YJ, Hurren R, Ruschak A, Climie S, Press B, Griffin C, Undzys E, Aman A, Al-awar R, Kay LE, O'Neill D, Trudel S, Slassi M, Schimmer AD.

Cell Death Dis. 2015 Jul 9;6:e1815. doi: 10.1038/cddis.2015.187.

16.

Factors involved in CLL pathogenesis and cell survival are disrupted by differentiation of CLL B-cells into antibody-secreting cells.

Ghamlouch H, Darwiche W, Hodroge A, Ouled-Haddou H, Dupont S, Singh AR, Guignant C, Trudel S, Royer B, Gubler B, Marolleau JP.

Oncotarget. 2015 Jul 30;6(21):18484-503.

17.

CyBorD induction therapy in clinical practice.

Areethamsirikul N, Masih-Khan E, Chu CM, Jimenez-Zepeda V, Reece DE, Trudel S, Kukreti V, Tiedemann R, Chen C.

Bone Marrow Transplant. 2015 Mar;50(3):375-9. doi: 10.1038/bmt.2014.288. Epub 2015 Jan 19.

PMID:
25599165
18.

Tyrosine phosphorylation of the Lyn Src homology 2 (SH2) domain modulates its binding affinity and specificity.

Jin LL, Wybenga-Groot LE, Tong J, Taylor P, Minden MD, Trudel S, McGlade CJ, Moran MF.

Mol Cell Proteomics. 2015 Mar;14(3):695-706. doi: 10.1074/mcp.M114.044404. Epub 2015 Jan 13.

19.

Absolute lymphocyte count as predictor of overall survival for patients with multiple myeloma treated with single autologous stem cell transplant.

Jimenez-Zepeda VH, Reece DE, Trudel S, Chen C, Franke N, Winter A, Tiedemann R, Kukreti V.

Leuk Lymphoma. 2015;56(9):2668-73. doi: 10.3109/10428194.2014.1003057. Epub 2015 Feb 24.

PMID:
25573201
20.

Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents.

Jimenez-Zepeda VH, Reece DE, Trudel S, Chen C, Tiedemann R, Kukreti V.

Bone Marrow Transplant. 2015 Feb;50(2):204-8. doi: 10.1038/bmt.2014.237. Epub 2014 Oct 27.

PMID:
25347006
21.

Oxidative stress is independent of inflammation in the neurodegenerative Sanfilippo syndrome type B.

Trudel S, Trécherel E, Gomila C, Peltier M, Aubignat M, Gubler B, Morlière P, Heard JM, Ausseil J.

J Neurosci Res. 2015 Mar;93(3):424-32. doi: 10.1002/jnr.23497. Epub 2014 Oct 21.

PMID:
25332157
22.

Differential regulation of FGFR3 by PTPN1 and PTPN2.

St-Germain JR, Taylor P, Zhang W, Li Z, Ketela T, Moffat J, Neel BG, Trudel S, Moran MF.

Proteomics. 2015 Jan;15(2-3):419-33. doi: 10.1002/pmic.201400259. Epub 2014 Dec 17.

23.

Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure.

St Bernard R, Chodirker L, Masih-Khan E, Jiang H, Franke N, Kukreti V, Tiedemann R, Trudel S, Reece D, Chen CI.

Bone Marrow Transplant. 2015 Jan;50(1):95-9. doi: 10.1038/bmt.2014.226. Epub 2014 Oct 6.

PMID:
25285800
24.

The clinical response to vemurafenib in a patient with a rare BRAFV600DK601del mutation-positive melanoma.

Trudel S, Odolczyk N, Dremaux J, Toffin J, Regnier A, Sevestre H, Zielenkiewicz P, Arnault JP, Gubler B.

BMC Cancer. 2014 Sep 29;14:727. doi: 10.1186/1471-2407-14-727.

25.

Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma.

Reece DE, Masih-Khan E, Atenafu EG, Jimenez-Zepeda VH, Anglin P, Chen C, Kukreti V, Mikhael JR, Trudel S.

Br J Haematol. 2015 Jan;168(1):46-54. doi: 10.1111/bjh.13100. Epub 2014 Aug 22.

PMID:
25146584
26.

Immediate utility of two approved agents to target both the metabolic mevalonate pathway and its restorative feedback loop.

Pandyra A, Mullen PJ, Kalkat M, Yu R, Pong JT, Li Z, Trudel S, Lang KS, Minden MD, Schimmer AD, Penn LZ.

Cancer Res. 2014 Sep 1;74(17):4772-82. doi: 10.1158/0008-5472.CAN-14-0130. Epub 2014 Jul 3.

27.

TLR9 Ligand (CpG Oligodeoxynucleotide) Induces CLL B-Cells to Differentiate into CD20(+) Antibody-Secreting Cells.

Ghamlouch H, Ouled-Haddou H, Guyart A, Regnier A, Trudel S, Claisse JF, Fuentes V, Royer B, Marolleau JP, Gubler B.

Front Immunol. 2014 Jun 16;5:292. doi: 10.3389/fimmu.2014.00292. eCollection 2014.

28.

Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma.

Reeder CB, Reece DE, Kukreti V, Mikhael JR, Chen C, Trudel S, Laumann K, Vohra H, Fonseca R, Bergsagel PL, Leis JF, Tiedemann R, Stewart AK.

Br J Haematol. 2014 Nov;167(4):563-5. doi: 10.1111/bjh.13004. Epub 2014 Jun 30. No abstract available.

PMID:
24974945
29.

Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia.

Jimenez-Zepeda VH, Reece DE, Trudel S, Chen C, Tiedemann R, Kukreti V.

Leuk Lymphoma. 2015 Jan;56(1):232-5. doi: 10.3109/10428194.2014.893304. Epub 2014 Jun 27. No abstract available.

PMID:
24884320
30.

Phorbol myristate acetate, but not CD40L, induces the differentiation of CLL B cells into Ab-secreting cells.

Ghamlouch H, Ouled-Haddou H, Guyart A, Regnier A, Trudel S, Claisse JF, Fuentes V, Royer B, Marolleau JP, Gubler B.

Immunol Cell Biol. 2014 Aug;92(7):591-604. doi: 10.1038/icb.2014.37. Epub 2014 May 6.

31.

Tolerability of Velcade (Bortezomib) subcutaneous administration using a maximum volume of 3 mL per injection site.

Ng P, Incekol D, Lee R, Paisley E, Dara C, Brandle I, Kaufman M, Chen C, Trudel S, Tiedemann R, Reece D, Kukreti V.

J Oncol Pharm Pract. 2015 Aug;21(4):285-92. doi: 10.1177/1078155214533367. Epub 2014 Apr 29.

PMID:
24781451
32.

Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone.

Sun HL, Atenafu EG, Yeboah E, Reece DE, Trudel S, Kukreti V, Masih-Khan E, Winter A, Chen C.

Leuk Lymphoma. 2015 Feb;56(2):407-14. doi: 10.3109/10428194.2014.915544. Epub 2014 Jul 7.

PMID:
24738975
33.

Long-term follow-up of a phase 2 trial of single agent lenalidomide in previously untreated patients with chronic lymphocytic leukaemia.

Chen CI, Paul H, Wang T, Le LW, Dave N, Kukreti V, Nong Wei E, Lau A, Bergsagel PL, Trudel S.

Br J Haematol. 2014 Jun;165(5):731-3. doi: 10.1111/bjh.12785. Epub 2014 Feb 24. No abstract available.

PMID:
24611934
34.

Synthesis and properties of cholesteric click-phospholes.

He X, Lin JB, Kan WH, Trudel S, Baumgartner T.

Org Lett. 2014 Mar 7;16(5):1366-9. doi: 10.1021/ol500129p. Epub 2014 Feb 14.

PMID:
24527856
35.

Oligoclonal and monoclonal bands after single autologous stem cell transplant in patients with multiple myeloma: impact on overall survival and progression-free survival.

Jimenez-Zepeda VH, Reece DE, Trudel S, Franke N, Winter A, Chen C, Tiedemann R, Kukreti V.

Leuk Lymphoma. 2014 Oct;55(10):2284-9. doi: 10.3109/10428194.2013.873537. Epub 2014 Feb 24.

PMID:
24354684
36.

Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies.

Minden MD, Hogge DE, Weir SJ, Kasper J, Webster DA, Patton L, Jitkova Y, Hurren R, Gronda M, Goard CA, Rajewski LG, Haslam JL, Heppert KE, Schorno K, Chang H, Brandwein JM, Gupta V, Schuh AC, Trudel S, Yee KW, Reed GA, Schimmer AD.

Am J Hematol. 2014 Apr;89(4):363-8. doi: 10.1002/ajh.23640. Epub 2014 Mar 3.

37.

Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis: experience of a single institution.

Jimenez-Zepeda VH, Franke N, Reece DE, Trudel S, Chen C, Delgado DH, Winter A, Mikhael JR, Tiedemann R, Kukreti V.

Br J Haematol. 2014 Mar;164(5):722-8. doi: 10.1111/bjh.12673. Epub 2013 Nov 25.

PMID:
24266428
38.

Characterization of a new V gene replacement in the absence of activation-induced cytidine deaminase and its contribution to human B-cell receptor diversity.

Ouled-Haddou H, Ghamlouch H, Regnier A, Trudel S, Herent D, Lefranc MP, Marolleau JP, Gubler B.

Immunology. 2014 Feb;141(2):268-75. doi: 10.1111/imm.12192.

39.

Inhibiting aberrant signal transducer and activator of transcription protein activation with tetrapodal, small molecule Src homology 2 domain binders: promising agents against multiple myeloma.

Page BD, Croucher DC, Li ZH, Haftchenary S, Jimenez-Zepeda VH, Atkinson J, Spagnuolo PA, Wong YL, Colaguori R, Lewis AM, Schimmer AD, Trudel S, Gunning PT.

J Med Chem. 2013 Sep 26;56(18):7190-200. doi: 10.1021/jm3017255. Epub 2013 Sep 13.

PMID:
23968501
40.

Water oxidation catalysis: electrocatalytic response to metal stoichiometry in amorphous metal oxide films containing iron, cobalt, and nickel.

Smith RD, Prévot MS, Fagan RD, Trudel S, Berlinguette CP.

J Am Chem Soc. 2013 Aug 7;135(31):11580-6. doi: 10.1021/ja403102j. Epub 2013 Jul 24.

PMID:
23883103
41.

A 2,6,9-hetero-trisubstituted purine inhibitor exhibits potent biological effects against multiple myeloma cells.

Shahani VM, Ball DP, Ramos AV, Li Z, Spagnuolo PA, Haftchenary S, Schimmer AD, Trudel S, Gunning PT.

Bioorg Med Chem. 2013 Sep 1;21(17):5618-28. doi: 10.1016/j.bmc.2013.04.080. Epub 2013 May 9.

PMID:
23810672
42.

Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents.

Chen CI, Masih-Khan E, Jiang H, Rabea A, Cserti-Gazdewich C, Jimenez-Zepeda VH, Chu CM, Kukreti V, Trudel S, Tiedemann R, Tsang R, Reece DE.

Br J Haematol. 2013 Aug;162(4):483-8. doi: 10.1111/bjh.12414. Epub 2013 Jun 15.

PMID:
23772701
43.

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study.

Jakubowiak AJ, Siegel DS, Martin T, Wang M, Vij R, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Harrison BL, Wong AF, Orlowski RZ, Jagannath S.

Leukemia. 2013 Dec;27(12):2351-6. doi: 10.1038/leu.2013.152. Epub 2013 May 14.

44.

D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma.

Gerrie AS, Mikhael JR, Cheng L, Jiang H, Kukreti V, Panzarella T, Reece D, Stewart KA, Trieu Y, Trudel S, Chen CI.

Br J Haematol. 2013 Jun;161(6):802-10. doi: 10.1111/bjh.12325. Epub 2013 Apr 18.

PMID:
23594335
45.

Photochemical route for accessing amorphous metal oxide materials for water oxidation catalysis.

Smith RD, Prévot MS, Fagan RD, Zhang Z, Sedach PA, Siu MK, Trudel S, Berlinguette CP.

Science. 2013 Apr 5;340(6128):60-3. doi: 10.1126/science.1233638. Epub 2013 Mar 28.

46.

Efficacy of thalidomide-based therapy following lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.

Kukreti V, Masih-Khan E, Young T, Chu CM, Jiang H, Trudel S, Chen C, Jimenez-Zepeda V, Reece DE.

Am J Hematol. 2013 Apr;88(4):337-8. doi: 10.1002/ajh.23394. Epub 2013 Mar 12. No abstract available.

47.

An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.

De P, Dey N, Terakedis B, Bergsagel PL, Li ZH, Mahadevan D, Garlich JR, Trudel S, Makale MT, Durden DL.

Cancer Chemother Pharmacol. 2013 Apr;71(4):867-81. doi: 10.1007/s00280-013-2078-0. Epub 2013 Jan 25.

48.

Dithieno[3,2-c:2',3'-e]-2,7-diketophosphepin: a unique building block for multifunctional π-conjugated materials.

He X, Borau-Garcia J, Woo AY, Trudel S, Baumgartner T.

J Am Chem Soc. 2013 Jan 23;135(3):1137-47. doi: 10.1021/ja310680x. Epub 2013 Jan 11.

PMID:
23308359
49.

A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial.

Stewart AK, Trudel S, Bahlis NJ, White D, Sabry W, Belch A, Reiman T, Roy J, Shustik C, Kovacs MJ, Rubinger M, Cantin G, Song K, Tompkins KA, Marcellus DC, Lacy MQ, Sussman J, Reece D, Brundage M, Harnett EL, Shepherd L, Chapman JA, Meyer RM.

Blood. 2013 Feb 28;121(9):1517-23. doi: 10.1182/blood-2012-09-451872. Epub 2013 Jan 7.

50.

Rapidity and quality of response to steroid-based induction therapy, without the addition of novel agents, does not affect post transplant outcomes in multiple myeloma.

Prica A, Trieu Y, Xu W, Reece DE, Trudel S, Kukreti V, Chen C.

Clin Lymphoma Myeloma Leuk. 2013 Feb;13(1):25-31. doi: 10.1016/j.clml.2012.08.008. Epub 2012 Oct 27.

PMID:
23107916

Supplemental Content

Loading ...
Support Center